Log in to search using one of your social media accounts:

 

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Conclusion This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy. Micro-Abstract Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Authors: Jungels C, Martinez Chanza N, Albisinni S, Mercier M, d'Haene N, Rorive S, Roumeguère T Abstract OBJECTIVES: There are only few predictive factors for response of non-musculo-invasive bladder cancer (NMIBC) to Bacillus Calmette-Guérin (BCG) therapy. Our study analyzed the results of the sequencing of new generation (NGS) targeted on 50 genes of oncological interest obtained on bladder resection parts in high-risk NMIBC patients treated with BCG, to describe this population from a molecular point of view and try to correlate these results in patients who present or not recurrence after BCG. ...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Ultrasound technique overcomes problems with current methods to diagnose the most common cancer in menScientists have announced the development of a highly accurate and reliable technique for diagnosing prostate cancer. The Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours. The method is non-invasive and cheaper than current detection techniques.Prostate cancer has become the most common cancer in men in the UK. One in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every yea...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Prostate cancer Health Society UK news Medical research Science Men's health & wellbeing Life and style Source Type: news
Medical research is reaching a new frontier with implants that can accurately spot early signs of cancer. Yet the road from laboratory to patient is long.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Hi Folks, Just signed up to this awesome forum. I'm a recent transplant from UK with FRCPath and about 8 years of experience as consultant pathologist. I understand that my path in USA = USMLE+Residency+Fellowship/Jobsearch. Are there any shortcuts from IMG folks' experience here that can get me a jump start in lieu of investing another 4-6 years? Many thanks in advance!
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums
This article provides an up-to-date review of biomarkers with promising characteristics to be prognostic markers for CCA reported in the past 5 years. The biomarkers are sub-classified into tissue and serum markers. Proteins, RNAs, peripheral blood cells etc., that are associated with aggressive phenotypes, signal pathways, chemo-drug resistance and those that reflect the survival time of CCA patients are evaluated for their prognostic prediction values. Expert commentary: CCAs are heterogeneous tumors of different histo-pathological subtypes and genetic influences and, therefore, potential markers should be validated in l...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
This article explores the public dying of journalist, writer, provocateur, public intellectual, and renowned atheist, Christopher Hitchens. It does so primarily through an analysis of television interviews given by Hitchens following his diagnosis with esophageal cancer in June 2010. Four key themes are identified as emerging from analysis of the interviews: (a) Hitchens' explicit sense of mission in challenging myths and superstitions surrounding cancer, dying, and death; (b) the personal experience of terminal illness and dying and the particular way (or style of dying) by which it is approached; (c) issues of regret and...
Source: Omega - Category: Palliative Care Authors: Tags: Omega (Westport) Source Type: research
Abstract Essential facts Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. The main categories are lymphoma, leukaemia, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms. In addition, there are subtypes of lymphoma and leukaemia, as well as more rare haematological cancers that have their own categories. There are also borderline conditions such as aplastic anaemia and other non-malignant bone marrow failure syndromes. The charity Bloodwise says 38,000 people in Britain are diagnosed every year with blood cancer or a related disor...
Source: Nursing Standard - Category: Nursing Authors: Tags: Nurs Stand Source Type: research
Conclusion In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in twelve patients (18%). HCS identification provides insight for improved and individualized treatment, and screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis, and advocates that with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germline testing. Teaser The clinical importance and anticipated results of geneti...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in 12 patients (18%). HCS identification provides insight for improved and individualized treatment, as well as screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis; with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germ-line testing. PMID: 27210295 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Conclusion Lenalidomide appears to yield a higher HI-E rate in non-del5q LR-MDS when used as first-line therapy after ESA treatments failure. If validated in larger cohorts, lenalidomide rather than azacitidine should be considered for first-line therapy after ESA treatment failure. Micro-Abstract In patients with lower-risk myelodysplastic syndromes (LR-MDS) in whom treatment with erythropoiesis-stimulating agents (ESAs) fail, optimal sequencing of lenalidomide and azanucleosides is unknown. In a retrospective analysis of patients who received azacitidine and lenalidomide, the erythroid hematologic improvement rate was 3...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants